Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 265 of 6351
-
Immunotherapy boosts radiation against early lung cancer
Disease control Stopped earlyThis study uses durvalumab (MEDI 4736), an experimental type of drug made by Astra Zeneca Pharmaceuticals, (limited partnership) LP, which in early studies has shown to possibly reduce the growth of certain types of lung cancer. The Investigators will enroll up to 105 subjects in…
Phase 1/2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a drug revive blood cell production in children with aplastic anemia?
Disease control CompletedThis is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractor…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with (1) high risk, relapsed/refractory (r/r) CD19+ B-ALL; (2) r/r DLBCL; (3) r/r CLL/SLL and (4) r/r FL and (5) r/r MCL.…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a prostate cancer drug boost breast cancer treatment?
Disease control OngoingThis is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after \~4 months on treatment.
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a pill replace chemo for stomach cancer in the elderly?
Disease control Recruiting nowThe study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to chemotherapy, through progression-free survival (PFS…
Phase 2 • Sponsor: The First Affiliated Hospital of Bengbu Medical University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New transplant approach offers hope for severe sickle cell disease
Disease control Completedmulticentric interventional biomedical research phase II, prospective, non-randomized evaluating a haploidentical marrow transplants after reduced-intensity conditioning and prevention of GvHD based on cyclophosphamide administration post transplantation in patients with severe s…
Phase 2 • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC
-
Immunotherapy combo shows promise in aggressive breast cancer trial
Disease control OngoingThis phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the bo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Heart valve surgery before symptoms? new study tests if early action saves lives
Disease control OngoingAortic stenosis is the most common valvular disease in the Western world. It is caused by progressive narrowing of the aortic valve leading to increased strain on the heart muscle which has to work increasingly hard to pump blood through the narrowed valve. Over time the heart mu…
Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 26, 2026 14:29 UTC
-
Electric pulses in the spine may ease diabetic nerve pain
Symptom relief CompletedThis post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (…
Sponsor: Nevro Corp • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can an immune booster fight rare brain tumors?
Disease control Stopped earlyBackground: More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Powerful cocktail shows promise against bone marrow cancer
Disease control CompletedThis study was a multi-center, open-label, single-arm, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 46 subjects were enrolled. The primary end point was the rate of stringent complete response (sC…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can a new drug combo tame a rare, untreated lymphoma?
Disease control OngoingBackground: Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL. Objective: To test a new treatment for PEL. Eligibility: Peo…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for brain cancer: immune drug combo shows promise
Disease control CompletedThis phase I/II trial studies the side effects and how well atezolizumab works in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New PET tracer spots hidden prostate cancer when PSA is low
Diagnosis OngoingThe purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Can a drug duo outsmart resistant lymphomas?
Disease control OngoingThe purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can an asthma drug shrink nasal polyps? a major trial seeks answers
Disease control CompletedNasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such …
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a dissolving heart valve spare kids from repeat surgeries?
Disease control OngoingThis is a multi-center prospective, single-arm, non-randomized, pivotal study that will continue to access the feasibility of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring right ventricular outflow tract correction or reconstruction due to congenital hea…
Sponsor: Xeltis • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Radiation boost may help stem cell transplants beat tough leukemia
Disease control OngoingThe study is a Phase II clinical trial. Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT).
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising combo for tough hodgkin lymphoma cases
Disease control OngoingThis phase II trial studies the side effects of nivolumab and to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) and does not respond to treatment (refractory). Immunoth…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowBackground: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, resear…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC